AgeX: randomising just one extra mammogram in 3 million women

With risk-appropriate regulation, UK electronic health records can facilitate large-scale studies. AgeX, the largest randomised treatment trial ever conducted, can assess realistically small effects of one extra mammographic screening invitation. Three million potentially compliant women have been randomised between invitation and control, and electronic follow-up is monitoring the effects on breast cancer incidence, treatment, and mortality.